Actualités

CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX's huge public offering didn't hurt either.

With the 10-Year Treasury yielding 4.48% and the Fed signaling more cuts ahead, income investors are hunting for yield that compounds. Bristol Myers Squibb (NYSE:BMY) offers a 4.39% yield backed by 94 consecutive years of dividend payments. The pharma giant is rebuilding around a Growth Portfolio (Eliquis, Camzyos, Breyanzi) while legacy drugs face generic erosion. ... A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb

Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies further down the clinical pipeline.

As Kevin Warsh steps up to lead the Federal Reserve, the case for interest-rate cuts is disappearing. Plus, investment newsletter commentary on AI”s circular ecosystem, emerging markets, and SpaceX.

Bristol Myers Squibb said on Wednesday it is partnering with Anthropic ‌to make its Claude AI model ‌available to over 30,000 employees in an effort to ​accelerate the discovery, development and delivery of new medicines. • Bristol said it will also leverage Claude Code, Anthropic's coding tool, and evaluate its ‌use in research, ⁠drug development, manufacturing and other commercial and medical affairs. • Agentic ​AI, which ​requires little human intervention, could increase clinical development productivity by about 35% to 45% ​over the ‌next five years, consultancy McKinsey said last ​year.

The deal helps solidify Anthropic’s commitment to the life sciences sector as it targets more enterprise clients.

Find insight on the deal between Hengrui Pharmaceuticals and Bristol Myers Squibb and more in the latest Market Talks covering the health care sector.

U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.

U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.

Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first q